FY2025 EPS Estimates for Indivior Boosted by Northland Capmk

Indivior PLC (NASDAQ:INDV - Free Report) - Research analysts at Northland Capmk raised their FY2025 earnings per share estimates for Indivior in a note issued to investors on Thursday, April 24th. Northland Capmk analyst C. Byrnes now expects that the company will earn $1.15 per share for the year, up from their previous estimate of $0.90. The consensus estimate for Indivior's current full-year earnings is $1.22 per share.

Other research analysts have also recently issued research reports about the company. Piper Sandler dropped their price target on Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a research report on Thursday, March 6th. RODMAN&RENSHAW upgraded Indivior to a "strong-buy" rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw started coverage on Indivior in a report on Tuesday, January 28th. They set a "buy" rating and a $16.00 target price on the stock.

Indivior Price Performance

NASDAQ INDV opened at $11.56 on Monday. The business has a 50 day moving average price of $9.48 and a 200 day moving average price of $10.34. The company has a market capitalization of $1.59 billion, a P/E ratio of -33.03 and a beta of 0.93. Indivior has a 1-year low of $7.33 and a 1-year high of $18.59.

Indivior (NASDAQ:INDV - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.19. The business had revenue of $266.00 million during the quarter, compared to the consensus estimate of $240.13 million. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%.

Hedge Funds Weigh In On Indivior

Several large investors have recently added to or reduced their stakes in the business. Deerfield Management Company L.P. Series C lifted its position in Indivior by 74.4% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 8,883,160 shares of the company's stock worth $110,418,000 after buying an additional 3,790,518 shares during the period. Newtyn Management LLC raised its holdings in shares of Indivior by 62.0% in the 4th quarter. Newtyn Management LLC now owns 1,406,531 shares of the company's stock worth $17,483,000 after purchasing an additional 538,426 shares during the period. Millennium Management LLC raised its holdings in shares of Indivior by 36.9% in the 4th quarter. Millennium Management LLC now owns 1,233,006 shares of the company's stock worth $15,326,000 after purchasing an additional 332,180 shares during the period. Ardsley Advisory Partners LP raised its holdings in shares of Indivior by 11.0% in the 4th quarter. Ardsley Advisory Partners LP now owns 1,200,000 shares of the company's stock worth $14,916,000 after purchasing an additional 119,050 shares during the period. Finally, CenterBook Partners LP raised its holdings in shares of Indivior by 105.5% in the 4th quarter. CenterBook Partners LP now owns 1,147,841 shares of the company's stock worth $14,268,000 after purchasing an additional 589,158 shares during the period. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.